New research data proves the value of accurate monitoring of patients after use of muscle relaxants

The results of the POPULAR (POst-anaesthesia PULmonary complications After use of muscle Relaxants) study including 211 sites and over 22,000 patients throughout Europe was published in The Lancet in February 2019. The study concluded that the use of neuromuscular blocking drugs in general anesthesia is associated with an increased risk of postoperative pulmonary complications.

Further analysis of the POPULAR database was presented at the ASA Meeting 2019. 4,182 cases that included quantitative neuromuscular monitoring were examined. Acceleromyography (AMG) was the most frequently used clinical technique to monitor neuromuscular function in POPULAR. Whether the technique of AMG is a valid tool for neuromuscular monitoring has become a major subject for debate according to the article, since a TOF-ratio higher than >95% had to be achieved in order to decrease the incidence of postoperative pulmonary complications. This underscores the need for precise neuromuscular monitoring in order to improve patient safety.

To quote the POPULAR re-analysis, “the greater the recovery from neuromuscular block, the lower the risk of complications related to residual paralysis.” 

 "Neuromuscular monitoring using Electromyography (EMG) is considered by many experts to be the current clinical gold standard" says Glenn Murphy, Clinical Professor in the Department of Anesthesiology, University of Chicago Pritzker School of Medicine, and Director of Clinical Research at NorthShore University Health System in Chicago, Illinois.

Over 70 million patients undergo surgery every year using both anesthetic and muscle relaxant drugs and research has shown that over 30 percent suffer from postoperative complications if objective patient monitoring is missing. TetraGraph is a unique CE- and FDA-cleared digital monitoring system that has been developed to help reduce postoperative complications in surgical patients receiving neuromuscular blocking drugs (NMBAs) as part of their general anesthesia. The TetraGraph is a cost-effective and user-friendly solution based on Electromyography (EMG) to stimulate peripheral nerves and with analysis based on proprietary algorithms. Results of muscle function are displayed accurately in real-time to enable correct dosing of drugs and safe extubation.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com       

TO THE EDITORS

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com